Dr Mark Kris continues a discussion about considerations related to the many faces of progression on systemic therapy.
Professor of Medicine, Weill Cornell Medical College; Attending Physician, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY
The next issue comes that, if indeed it is successful in palliating the symptom and coming up with a therapy to do that, do you want to continue the systemic therapy? We have plenty of examples now of what I’ll call Asymptomatic progression is probably the toughest thing and the one that really takes a large amount of thought. I think, again, symptoms are really important. If you have a symptom, it’s a whole different ballgame. You have to palliate the symptom and then come up with an anticancer strategy to, in the long term, alleviate that symptom.
Another important thing is the rate of growth. I remember many years ago, I went to a lecture by Tony Mok, and he showed a series of scans of a person with EGFR-mutant lung cancer. Over a period of 3 years, in the scans that he showed, the cancer had grown maybe on each scan by 10%.
Lung Carcinoma Cancer Of The Lung Toxicology Toxicity Poisoning Toxins Biologic Therapy Biologics Patient Safety Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Targeted Therapy Targeted Cancer Therapy Adverse Effects Side Effects Cancer Pain Pain From Cancer Cancer-Related Pain Healthcare And Medical Technology Health And Medical Tech Health And Med Tech
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Navigating the Faces of Progression in Systemic TherapyThis talk delves into the complexities of defining disease progression in the context of systemic therapy. Expert insights guide clinicians on prioritizing patient symptoms, exploring alternative treatment options, and evaluating the accuracy of progression documentation.
Read more »
Early Success Seen With CAR T-Cell Therapy for Systemic SclerosisA case series showed that chimeric antigen receptor T-cell therapy targeting CD19 halted the progression of fibrotic organ manifestations in six patients with diffuse cutaneous systemic sclerosis.
Read more »
Group therapy, like individual therapy, may have a philosophical aspect.Interest in intersections between philosophy and therapy has tended to focus on the individual. But there is also a rich tradition of group therapy with a philosophical aspect.
Read more »
Combating Age-Related Decline: Testosterone Replacement Therapy and Peptide TherapyThis article explores the effects of sarcopenia, muscle loss due to aging, and the impact of declining testosterone levels on men. It highlights the benefits of testosterone replacement therapy (TRT) in alleviating symptoms and restoring vitality. Additionally, it introduces peptide therapy, a promising approach for stimulating natural growth hormone production and reducing visceral fat.
Read more »
Marvel Rivals Crossplay Launch - Cross-Progression Still MissingMarvel Rivals offers crossplay functionality at launch but lacks cross-progression. The developer, NetEase Games, is actively working on implementing this feature, but it may take some time due to technical complexities.
Read more »
Tafasitamab Plus Lenalidomide and Rituximab Improves Progression-Free Survival in Relapsed or Refractory Follicular LymphomaA phase 3 clinical trial demonstrates that adding tafasitamab to lenalidomide and rituximab significantly extends progression-free survival in patients with relapsed or refractory follicular lymphoma.
Read more »